Dyne Therapeutics, Inc. (DYN)
26.00
-0.10
(-0.40%)
USD |
NASDAQ |
Aug 24, 16:00
26.00
0.00 (0.00%)
After-Hours: 20:00
Dyne Therapeutics Shareholders Equity (Quarterly) : 702.15M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 702.15M |
| March 31, 2026 | 865.06M |
| December 31, 2025 | 972.13M |
| September 30, 2025 | 691.78M |
| June 30, 2025 | 571.44M |
| March 31, 2025 | 668.97M |
| December 31, 2024 | 629.84M |
| September 30, 2024 | 705.54M |
| June 30, 2024 | 775.19M |
| March 31, 2024 | 478.06M |
| December 31, 2023 | 91.29M |
| September 30, 2023 | 152.04M |
| June 30, 2023 | 206.88M |
| March 31, 2023 | 241.94M |
| Date | Value |
|---|---|
| December 31, 2022 | 252.36M |
| September 30, 2022 | 249.74M |
| June 30, 2022 | 287.06M |
| March 31, 2022 | 336.46M |
| December 31, 2021 | 368.20M |
| September 30, 2021 | 414.12M |
| June 30, 2021 | 452.60M |
| March 31, 2021 | 478.26M |
| December 31, 2020 | 342.37M |
| September 30, 2020 | 366.84M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 14.04M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Vor Biopharma, Inc. | -200.20M |
| Neurocrine Biosciences, Inc. | 3.694B |
| Recursion Pharmaceuticals, Inc. | 915.00M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 994.01M |
| Total Liabilities (Quarterly) | 291.86M |
| Debt to Equity Ratio | 0.3323 |
| Current Ratio | 12.02 |
| Net Debt Paydown Yield | -1.14% |